deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT03731442

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients: A Prospective, Multicenter Clinical Trial

Sponsor: Anyang Tumor Hospital

Conditions Esophageal Cancer
Interventions Elective field irradiation Involved field irradiation PEG-rhG-CSF Paclitaxel Platinum
Updated 8 times since 2018 Last updated: Dec 10, 2018 Started: Nov 1, 2018 Primary completion: Oct 31, 2022 Completion: Oct 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Esophageal Cancer and is currently actively recruiting participants. Anyang Tumor Hospital leads this study, which shows 8 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshotRecruiting~Jan 2019 – ~Jan 2021 · 24 months · monthly snapshotRecruiting~Jan 2021 – ~Nov 2022 · 22 months · monthly snapshotRecruiting~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshotRecruiting~Dec 2022 – ~Oct 2023 · 10 months · monthly snapshotRecruiting~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – present · 22 months · monthly snapshotRecruiting

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  3. Oct 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  4. Dec 2022 — Oct 2023 [monthly]

    Recruiting PHASE3

  5. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

▶ Show 3 earlier versions

  1. Jan 2021 — Nov 2022 [monthly]

    Recruiting PHASE3

  2. Jan 2019 — Jan 2021 [monthly]

    Recruiting PHASE3

  3. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Anyang Tumor Hospital
  • Chinese Academy of Medical Sciences
  • Fujian Cancer Hospital
  • Hebei Medical University Fourth Hospital
  • Peking University Cancer Hospital & Institute
  • The First Affiliated Hospital with Nanjing Medical University
  • Tianjin Medical University Cancer Institute and Hospital
Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations